Personalis (NASDAQ:PSNL) Upgraded by Zacks Investment Research to “Hold”

Personalis (NASDAQ:PSNL – Get Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued on Saturday, Zacks.com reports.

According to Zacks, “Personalis Inc. is a cancer genomics company. It is engaged in the development of therapies by providing molecular data about each patient’s cancer and immune response. Personalis Inc. is based in Menlo Park, California. “

PSNL has been the topic of several other reports. Citigroup cut their target price on shares of Personalis from $30.00 to $18.00 and set a “buy” rating on the stock in a report on Friday, February 25th. Bank of America upgraded shares of Personalis from a “neutral” rating to a “buy” rating and cut their target price for the stock from $27.00 to $23.00 in a report on Friday, January 7th. Oppenheimer cut their target price on shares of Personalis from $30.00 to $24.00 and set an “outperform” rating on the stock in a report on Friday, February 25th. HC Wainwright cut their target price on shares of Personalis from $50.00 to $38.00 and set a “buy” rating on the stock in a report on Friday, February 25th. Finally, BTIG Research reiterated a “buy” rating and issued a $30.00 target price on shares of Personalis in a report on Friday, January 7th. Three research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $26.88.

Shares of PSNL stock opened at $5.91 on Friday. Personalis has a 52-week low of $5.87 and a 52-week high of $28.47. The stock has a market cap of $267.04 million, a PE ratio of -3.99 and a beta of 1.56. The firm’s 50 day moving average price is $8.55 and its two-hundred day moving average price is $12.70.

Personalis (NASDAQ:PSNL – Get Rating) last announced its quarterly earnings data on Thursday, February 24th. The company reported ($0.45) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.51) by $0.06. Personalis had a negative net margin of 76.29% and a negative return on equity of 19.72%. The firm had revenue of $20.68 million for the quarter, compared to analysts’ expectations of $20.70 million. During the same period last year, the firm earned ($0.34) earnings per share. As a group, analysts forecast that Personalis will post -2.49 EPS for the current year.

In other Personalis news, CFO Aaron Tachibana sold 4,511 shares of Personalis stock in a transaction on Wednesday, March 2nd. The shares were sold at an average price of $10.18, for a total value of $45,921.98. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, major shareholder Lightspeed Venture Partners Se purchased 48,989 shares of the stock in a transaction on Wednesday, March 2nd. The stock was acquired at an average price of $9.96 per share, for a total transaction of $487,930.44. The disclosure for this purchase can be found here. Over the last 90 days, insiders have sold 5,687 shares of company stock worth $57,717. 5.80% of the stock is currently owned by company insiders.

A number of hedge funds have recently modified their holdings of the business. ARK Investment Management LLC increased its stake in Personalis by 6.1% in the 1st quarter. ARK Investment Management LLC now owns 5,184,784 shares of the company’s stock valued at $42,463,000 after buying an additional 296,669 shares during the last quarter. BlackRock Inc. increased its stake in Personalis by 24.3% in the 4th quarter. BlackRock Inc. now owns 4,389,333 shares of the company’s stock valued at $62,637,000 after buying an additional 857,372 shares during the last quarter. Millennium Management LLC increased its stake in Personalis by 533.6% in the 4th quarter. Millennium Management LLC now owns 1,350,852 shares of the company’s stock valued at $19,277,000 after buying an additional 1,137,636 shares during the last quarter. Nikko Asset Management Americas Inc. grew its position in shares of Personalis by 1.1% in the 3rd quarter. Nikko Asset Management Americas Inc. now owns 1,085,026 shares of the company’s stock valued at $20,485,000 after acquiring an additional 12,309 shares during the period. Finally, Wellington Shields Capital Management LLC grew its position in shares of Personalis by 1.3% in the 4th quarter. Wellington Shields Capital Management LLC now owns 922,990 shares of the company’s stock valued at $13,171,000 after acquiring an additional 12,204 shares during the period. Hedge funds and other institutional investors own 67.63% of the company’s stock.

Personalis Company Profile (Get Rating)

Personalis, Inc operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies and large-scale genetic research programs. It offers NeXT Platform, which provides data analysis for tumor and its immune microenvironment, from a single limited tissue or plasma sample; ImmunoID Next for tumor profiling from tissue; NeXT Liquid Biopsy for tumor profiling from plasma; NeXT Personal, a liquid biopsy offering for personalized tumor tracking for patients; NeXT Dx Test, a genomic cancer profiling test enabling composite biomarkers for cancer treatment; and NeXT SHERPA and NeXT NEOPS for neoantigen prediction capabilities.

Read More